(Finance) – The European Commission has authorized the mRNA vaccine “mResvia”to immunize adults over 60 years of age against lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection. RSV is a common respiratory virus, usually with mild symptoms, but with potentially serious consequences for vulnerable people, including the elderly.
“Vaccination saves lives,” commented the Commissioner for Health and Food Safety, Stella Kyriakides – In a strong European Health Union, we are determined to ensure that everyone has access to the protection they need against serious diseases. This approval of the first mRNA vaccine against RSV clearly shows the importance of innovation when it comes to protecting the health of our citizens.”
mResvia Authorization Arrives before the fall/winter seasonwhen respiratory infections such as RSV tend to peak across the EU. It follows a positive scientific assessment by the European Medicines Agency (EMA) in June 2024. It is now up to national authorities in each Member State to decide whether and how they will use the vaccine, in line with their national vaccination plans.
mResvia, developed by Modernis the First mRNA vaccine to be authorised in the EU for a disease other than COVID-19. Other vaccines against respiratory syncytial virus were authorised by the Commission in 2023, to protect vulnerable groups, including newborns.